The very same day it released results from a study comparing implantable cardioverter–defibrillators and cardiac-resynchronization therapy devices, Boston Scientific Corp. touted results from a second study demonstrating the effectiveness of the ICD devices.
The Natick, Mass.-based medical devices monolith said long-term data from its Prevention of Sudden Cardiac Death II study indicate that ICDs reduced the risk of death by 44 percent after implantation in patients who’d suffered a heart attack.
The study examined outcomes in the cases of 10,612 heart attack survivors between 2002 and 2005 in 19 centers in Germany.
Earlier today, the company’s stock waxed and waned in response to the results from the CRT-D/ICD trial, known as the MADIT-CRT study.